CSL (OTCMKTS:CSLLY) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of CSL (OTCMKTS:CSLLYGet Rating) from a sell rating to a hold rating in a research report report published on Wednesday, Zacks.com reports.

According to Zacks, “CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The company’s operating segments consists of CSL Behring and bioCSL. CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. bioCSL segment manufactures, sells and distributes vaccines, antivenoms and other pharmaceutical products primarily in Australia and New Zealand; as well as also manufactures and markets in vitro diagnostic products through Immunohaematology. It operates primarily in Germany, Switzerland and the United States. CSL Ltd. is headquartered in Parkville, Australia. “

CSLLY stock opened at $100.56 on Wednesday. The firm has a fifty day moving average price of $97.73 and a 200 day moving average price of $101.70. CSL has a fifty-two week low of $85.07 and a fifty-two week high of $117.49. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.94 and a quick ratio of 3.43.

About CSL (Get Rating)

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.

Read More

Get a free copy of the Zacks research report on CSL (CSLLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.